ReviewDigestive diseases and sciences2011
Nonalcoholic fatty liver disease and the coronary artery disease.
Review in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 69 citations in OpenAlex.
- A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children.Childhood obesity (Print) · 2013Trial
- Correlation between controlled attenuation parameter values with SYNTAX score in patients with significant coronary artery disease.Scientific reports · 2024Article
- New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis.Life (Basel, Switzerland) · 2022Review
- Ultrasonographically detected hepatosteatosis independently predicts the presence and severity of coronary artery disease.African health sciences · 2022Article
- Growth performance, fatty acid composition, and lipid metabolism are altered in groupers (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2022Article
- Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.Diagnostics (Basel, Switzerland) · 2021Review
- Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study.Obesity facts · 2021Article
- Middle- and high-molecular weight adiponectin levels in relation to nonalcoholic fatty liver disease.Journal of clinical laboratory analysis · 2020Article
- B-type peptides to predict post-liver transplant mortality: systematic review and meta-analysis.Canadian liver journal · 2019Review
- Steatosis in South African women: How much and why?PloS one · 2018Article
- Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Role of NCAN rs2228603 polymorphism in the incidence of nonalcoholic fatty liver disease: a case-control study.Lipids in health and disease · 2016Article
- Association between retinal artery lesions and nonalcoholic fatty liver disease.Hepatology international · 2015Article
- Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease.Hepatitis monthly · 2015Article
- Diagnostic potential of differentially expressed Homer1, IL-1β, and TNF-α in coronary artery disease.International journal of molecular sciences · 2014Article
- Integrated microRNA-mRNA analysis of coronary artery disease.Molecular biology reports · 2014Article
- Hepato-cardiac disorders.World journal of hepatology · 2014Review
- Surgical treatment of nonalcoholic fatty liver disease in severely obese patients.Hepatic medicine : evidence and research · 2014Review
- Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease.Atherosclerosis · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and is recognized as part of the metabolic syndrome (MetS). Patients with NAFLD have a lower life expectancy compared to the general population, with coronary artery disease (CAD) as the leading cause of death.
aimsWe aim to address the epidemiological data of CAD, the possible pathogenesis or linkage mechanisms of NAFLD and atherosclerosis and the strategies to reduce the CAD risk in NAFLD patients.
methodsWe reviewed data from a Medline and PubMed search which was performed to identify relevant literature using search terms "NAFLD," "metabolic syndrome" and "coronary artery disease."
resultsPatients with steatohepatitis, a part of the spectrum of NAFLD, have more cardiovascular events than patients without steatohepatitis. However, the association between liver histological progression and the risk of CAD events is not linear. A multidisciplinary approach to NAFLD patients based on controlling related risk factors and monitoring for CAD risks and liver complications is necessary. The combination of lifestyle modification with pharmacological treatment tailored to each individual's risk factors needs to be considered. There is a need for more research on primary prevention for CAD in NAFLD patients and interventional studies for determining the nature of the relationship between NAFLD and CAD.
conclusionsNAFLD is recognized as part of the MetS and increases cardiovascular risks. Therefore, a multidisciplinary approach to these patients of controlling the related risk factors and monitoring for cardiovascular and liver complications must be done.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.